Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

Long-term durability and dose escalation patterns in infliximab therapy for psoriasis.

Luber AJ, Tsui CL, Heinecke GM, Lebwohl MG, Levitt JO.

J Am Acad Dermatol. 2014 Mar;70(3):525-32. doi: 10.1016/j.jaad.2013.10.059. Epub 2013 Dec 31.

PMID:
24388425
2.

Long-term study of infliximab for psoriasis in daily practice: drug survival depends on combined treatment, obesity and infusion reactions.

Spertino J, Lopez-Ferrer A, Vilarrasa E, Puig L.

J Eur Acad Dermatol Venereol. 2014 Nov;28(11):1514-21.

PMID:
25493314
3.

Infliximab treatment for psoriasis in 120 patients on therapy for a minimum of one year: a review.

Kamili QU, Miner A, Hapa A, Menter A.

J Drugs Dermatol. 2011 May;10(5):539-44.

PMID:
21533302
4.

Infliximab for the treatment of psoriasis in the U.K.: 9 years' experience of infusion reactions at a single centre.

Wee JS, Petrof G, Jackson K, Barker JN, Smith CH.

Br J Dermatol. 2012 Aug;167(2):411-6. doi: 10.1111/j.1365-2133.2012.10931.x. Epub 2012 Jun 11.

PMID:
22404545
5.

Long-term maintenance treatment of moderate-to-severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort.

Dalaker M, Bonesrønning JH.

J Eur Acad Dermatol Venereol. 2009 Mar;23(3):277-82. doi: 10.1111/j.1468-3083.2008.03039.x. Epub 2008 Dec 19.

PMID:
19207642
6.
7.
8.
9.

Re-induction as a possible alternative modality of dose escalation of infliximab: a prospective evaluation in a small series of psoriatic patients.

Cassano N, Puglisi Guerra A, Malara C, Loconsole F, Galluccio A, Pezza M, Vena GA.

Int J Immunopathol Pharmacol. 2007 Jul-Sep;20(3):647-50.

PMID:
17880779
10.

Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).

Barker J, Hoffmann M, Wozel G, Ortonne JP, Zheng H, van Hoogstraten H, Reich K.

Br J Dermatol. 2011 Nov;165(5):1109-17. doi: 10.1111/j.1365-2133.2011.10615.x.

PMID:
21910713
11.

Psoriasis and its treatment with infliximab-mediated tumor necrosis factor alpha blockade.

Winterfield L, Menter A.

Dermatol Clin. 2004 Oct;22(4):437-47, ix. Review.

PMID:
15450339
13.

Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre.

Antoniou C, Stefanaki I, Stratigos A, Moustou E, Vergou T, Stavropoulos P, Avgerinou G, Rigopoulos D, Katsambas AD.

Br J Dermatol. 2010 May;162(5):1117-23. doi: 10.1111/j.1365-2133.2009.09578.x. Epub 2009 Nov 10.

PMID:
19906069
14.

Long-term management of generalized pustular psoriasis with infliximab: case series.

Routhouska SB, Sheth PB, Korman NJ.

J Cutan Med Surg. 2008 Jul-Aug;12(4):184-8.

PMID:
18627699
15.

A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment.

Hroch M, Chladek J, Simkova M, Vaneckova J, Grim J, Martinkova J.

J Eur Acad Dermatol Venereol. 2008 Jan;22(1):19-24. Epub 2007 Nov 19.

PMID:
18031504
16.

Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis.

Taxonera C, Barreiro-de Acosta M, Calvo M, Saro C, Bastida G, Martín-Arranz MD, Gisbert JP, García-Sánchez V, Marín-Jiménez I, Bermejo F, Chaparro M, Ponferrada Á, Martínez-Montiel MP, Pajares R, de Gracia C, Olivares D, Alba C, Mendoza JL, Fernández-Blanco I.

Dig Dis Sci. 2015 Oct;60(10):3075-84. doi: 10.1007/s10620-015-3735-4. Epub 2015 Jun 5.

PMID:
26044830
17.

Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study.

Esposito M, Gisondi P, Cassano N, Ferrucci G, Del Giglio M, Loconsole F, Giunta A, Vena GA, Chimenti S, Girolomoni G.

Br J Dermatol. 2013 Sep;169(3):666-72. doi: 10.1111/bjd.12422.

PMID:
23647206
18.

Infliximab in the treatment of psoriasis in patients previously treated with etanercept.

Haitz KA, Kalb RE.

J Am Acad Dermatol. 2007 Jul;57(1):120-5. Epub 2007 May 7.

PMID:
17482715
19.

Sustained efficacy and safety of infliximab in psoriasis: a retrospective study of 73 patients.

Krathen RA, Berthelot CN, Hsu S.

J Drugs Dermatol. 2006 Mar;5(3):251-4.

PMID:
16573258
20.

Infliximab maintains durable response and facilitates catch-up growth in luminal pediatric Crohn's disease.

Church PC, Guan J, Walters TD, Frost K, Assa A, Muise AM, Griffiths AM.

Inflamm Bowel Dis. 2014 Jul;20(7):1177-86. doi: 10.1097/MIB.0000000000000083.

PMID:
24865777
Items per page

Supplemental Content

Write to the Help Desk